Protocol for the examination of specimens from patients with non-Hodgkin lymphoma/lymphoid neoplasms

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 6, 2010, Pages

  Hussong, Jerry W ^a   Arber, Daniel A ^c   Bradley, Kyle T ^d   Brown, Michael S ^e   Chang, Chung Che ^f   De Baca, Monica E ^g   Ellis, David W ^h   Foucar, Kathryn ⁱ   Hsi, Eric D ^j   Jaffe, Elaine S ^k   Lill, Michael ^b   McClure, Stephen P ^l   Medeiros, L Jeffrey ^m   Perkins, Sherrie L ⁿ  

^a Cedars Sinai Medical Center   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e Yellowstone Pathology Institute Inc   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g Physicians Laboratory Ltd   (United States)

^h FLINDERS MEDICAL CENTRE   (Australia)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l Presbyterian Pathology Group   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY; CLASSIFICATION; CLINICAL PROTOCOL; HUMAN; LYMPHOMA; NONHODGKIN LYMPHOMA; PATHOLOGY; STANDARD; WORLD HEALTH ORGANIZATION;

BIOPSY; CLINICAL PROTOCOLS; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; WORLD HEALTH ORGANIZATION;

EID: 77953189627     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hussong JW, Arber DA, Bradley KT, et al. Protocol for the Examination of Specimens From Patients With Hodgkin Lymphoma-Reporting on Cancer Specimens: Case Summaries and Background Documentation. Northfield, IL: College of American Pathologists; 2009.
2. Knowles D, ed. Neoplastic Hematopathology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
3. Mills S, ed. Histology for Pathologists. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours; vol 3.
5. Swerdlow S, Campo E, Harris N, et al, eds. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. World Health Organization Classification of Tumours; vol 2.
6. Crump M, Gospodarowicz MK. Non-Hodgkin malignant lymphoma. In: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind C, eds. Prognostic Factors in Cancer. New York, NY: Wiley-Liss; 2001: 689-703.
7. Hsi E, Goldblum J, eds. Hematopathology. Philadelphia, PA: Churchill Livingstone Elsevier; 2007.
8. Craig F, Foon K. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941-3967.
9. Jaffe E, Banks P, Nathwani B, et al. Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. Mod Pathol. 2004;17(1):131-135.
10. Bagg A. Molecular diagnosis in lymphomas. Curr Oncol Rep. 2004;6(5):369-379.
11. Carbone P, Kaplan H, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1861.
12. Lister T, Crowther D, Sutcliffe S, et al. Report of a committee convened to discuss the evaluation and staging of patient's with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-1636.
13. Armitage J, Cheson B, Anderson K, et al. Lymphoid neoplasms. In: Edge SB, Byrd DR, Carducci MA, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009: 599-628.
14. Sobin LH, Gospodarowicz M, Wittekind Ch, eds. UICC TNM Classification of Malignant Tumours. 7th ed. New York, NY: Wiley-Liss. In press.
15. Durie B, Salmon S. A clinical staging system for multiple myeloma: correlation of measured myeloma mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
16. Cairo M, Raetz E, Perkins S. Non-Hodgkin's lymphoma in children. In: Kufe P, Weishelbuam R, et al, eds. Cancer Medicine. 7th ed. London, United Kingdom: BC Decker; 2006: 1962-1975.
17. Armitage J. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55(6):368-376.
18. Ansell S, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80(8):1087-1097.
19. Kwee T, Kwee R, Nievelstein R. Imaging in staging malignant lymphoma: a systematic review. Blood. 2008;111(2):504-516.
20. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1708-1709.
21. Zelenetz A, Hoppe R. NCCN: non-Hodgkin's lymphoma. Cancer Control. 2001: 8 (6 suppl 2) : 102-113.
22. Arber DA. Molecular approach to non-Hodgkin's lymphoma. J Mol Diagn. 2000;2(4):178-190.
23. Bagg A. Role of molecular studies in the classification of lymphoma. Expert Rev Mol Diagn. 2004;4(1):83-97.
24. Sen F, Vega F, Medeiros LJ. Molecular genetic methods in the diagnosis of hematologic neoplasms. Semin Diagn Pathol. 2002;19(2):72-93.
25. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-1392. (Pubitemid 24273002)
26. Chan JK, Banks PM, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group: a summary version. Am J Clin Pathol. 1995;103(5):543-560.
27. Nguyen D, Diamond L, Braylan R. Flow Cytometry in Hematopathology: A Visual Approach to Data Analysis and Interpretation. Totowa, NJ: Humana Press; 2003.
28. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
29. Shipp M. Prognostic factors in aggressive non-Hodgkin lymphoma. Blood. 1994;83(5):1165-1173.
30. Hoskins PJ, Ng V, Spinelli JJ, et al. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol. 1991;9(2):220-226.
31. Cowan RA, Jones M, Harris M, et al. Prognostic factors in high and intermediate grade non-Hodgkin lymphoma. Br J Cancer. 1989;59(2):276-282.
32. Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10(4):489-497.
33. Osterman B, Cavallin-Stahl E, Hagberg H, et al. High-grade non-Hodgkin lymphoma stage I: a retrospective study of treatment, outcome, and prognostic factors in 213 patients. Acta Oncol. 1996;35(2):171-177.
34. Sehn L, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861.
35. Solal-Celigny P, Roy P, Colombat P, et al. Follicular Lymphoma International Prognostic Index. Blood. 2004;104(5):1258-1265.
36. Velasquez WS, Jagannath S, Tucker SL, et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood. 1989;74(2):551-557.